
Aclaris Therapeutics Announces Q1 2024 Financial Performance: Corporate Updates Shift Focus to Novel, Capital-Efficient Immuno-Inflammatory Therapies
WAYNE, PA — Aclaris Therapeutics (NASDAQ: ACRS), a noted bio-pharmaceutical firm, has made public its financial results for the first quarter of 2024. The announcement was made amidst an outline …
Aclaris Therapeutics Announces Q1 2024 Financial Performance: Corporate Updates Shift Focus to Novel, Capital-Efficient Immuno-Inflammatory Therapies Read More